AAD 2026Abstract 71352RCT
Efficacy of izokibep, a novel interleukin-17A inhibitor, in moderate to severe hidradenitis suppurativa
Week 32 results from a randomized, double-blind, placebo-controlled, multicenter, phase 3 study
Papp KA, Bechara FG, Porter ML, Forman SB, Sofen H, Szepietowski JC, Ehst BD, Martorell A, Mpofu S, Frejd FY, Kimball AB
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Hidradenitis suppurativa
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.781 · Not in PubMed: details from Crossref